Search
-
Leveraging Real-World Evidence to Drive Pricing & Access
The importance of Multiple Data Source Integration and Value Attribution in Multi-Component Disease Management.
-
The Path to Techquity
Ipsos partnered with the HLTH Foundation to shine a light on existing health tech-related inequities in the US and identify opportunities for the industry to address techquity gaps.
-
Four in ten single French people feel out of place because of their relationship status
Ipsos conducted for Badoo the first edition of an annual barometer on the mental health of single people facing social pressure. The results expose the consequences of defining a partnered couple as "normal”.
-
Lifting of COVID restrictions fails to trigger an uptick in global consumer confidence
Expectations Index drops significantly in Germany and Italy
-
Three insights about why workers are quitting
Using social, survey, and search data our analysis uncovers new motivations driving worker resignations.
-
Flash Eurobarometer: Women in times of COVID-19
Marking International Women’s Day 2022 on 8 March, the European Parliament, Directorate General for Communication, commissioned Ipsos European Public Affairs to conduct a new Flash Eurobarometer survey to gather women's opinions on the impact of the COVID-19 pandemic.
-
IWD 2022: Women are more likely to perceive institutional bias against them
Women are more likely to perceive institutional bias against women than men, particularly governments and social media.
-
Ipsos Update - March 2022
Opinion polling, the year ahead in Brazil, gender inequality in Japan, and the future of ageing are all featured topics in this month’s round-up of research and thinking from Ipsos teams around the world.
-
Covid-19: Expectations and vaccination
Majorities in each of 30 countries believe we will never fully stop the spread of COVID, but views on vaccination mandates vary widely.
-
A Year in Oncology: A review of 2021 drug approvals in US, Europe and Japan
Whilst the global COVID-19 pandemic continued throughout 2021, new oncology drug and indication approvals maintained momentum across the US, Europe and Japan. These included continued roll-out and label expansions of Immuno-Oncology (I-O) therapies, along with treatments approved in Japan ahead of other global regions.